Bristows successful for Novartis against Celltrion’s UK invalidity claim over Xolair
Biosimilars In the dispute with Celltrion over the bronchial asthma drug omalizumab, the UK Excessive Court has ruled in favour...
Bristows
Biosimilars In the dispute with Celltrion over the bronchial asthma drug omalizumab, the UK Excessive Court has ruled in favour...
